3,209 Shares in Quest Diagnostics Incorporated $DGX Bought by MQS Management LLC

Posted by on May 23rd, 2026

MQS Management LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,209 shares of the medical research company’s stock, valued at approximately $557,000.

Several other institutional investors have also bought and sold shares of DGX. Paradiem LLC acquired a new position in shares of Quest Diagnostics during the 4th quarter valued at $13,652,000. Lebenthal Global Advisors LLC lifted its holdings in shares of Quest Diagnostics by 117.5% in the third quarter. Lebenthal Global Advisors LLC now owns 5,034 shares of the medical research company’s stock valued at $959,000 after buying an additional 2,720 shares during the period. Rakuten Investment Management Inc. acquired a new stake in shares of Quest Diagnostics in the third quarter valued at $4,713,000. Union Bancaire Privee UBP SA bought a new position in Quest Diagnostics during the fourth quarter valued at about $1,517,000. Finally, Cibc World Market Inc. grew its holdings in Quest Diagnostics by 209.6% during the third quarter. Cibc World Market Inc. now owns 7,765 shares of the medical research company’s stock worth $1,480,000 after acquiring an additional 5,257 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Up 0.7%

Shares of NYSE DGX opened at $195.23 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.67. Quest Diagnostics Incorporated has a 12 month low of $164.65 and a 12 month high of $213.50. The company has a market cap of $21.61 billion, a price-to-earnings ratio of 21.57, a P/E/G ratio of 2.31 and a beta of 0.60. The business has a fifty day simple moving average of $194.85 and a 200-day simple moving average of $190.46.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter last year, the business posted $1.94 EPS. Quest Diagnostics’s revenue was up 9.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Sell-side analysts predict that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics announced that its board has approved a share repurchase plan on Tuesday, February 10th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 4.7% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be paid a dividend of $0.86 per share. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.8%. Quest Diagnostics’s dividend payout ratio is currently 38.01%.

Insider Activity

In other Quest Diagnostics news, SVP Patrick Plewman sold 2,855 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $588,729.55. Following the completion of the sale, the senior vice president directly owned 15,198 shares of the company’s stock, valued at approximately $3,133,979.58. This represents a 15.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael E. Prevoznik sold 3,878 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $799,682.38. Following the sale, the senior vice president directly owned 37,557 shares of the company’s stock, valued at $7,744,628.97. This represents a 9.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 14,919 shares of company stock valued at $3,072,899 over the last ninety days. Corporate insiders own 0.88% of the company’s stock.

Analysts Set New Price Targets

DGX has been the topic of several research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Citigroup raised their price objective on shares of Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a research report on Tuesday, February 10th. Barclays raised their price objective on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Robert W. Baird raised their price objective on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Finally, Evercore set a $225.00 price objective on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $216.58.

View Our Latest Stock Analysis on DGX

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Featured Articles

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.